Company profile

Mirador Therapeutics

Immuno-fibrotic disease (private, $250M Series B)

Privately held: no public share price · USA

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
MT-201
Phase 2
TL1A · IL-23 p19Multispecific antibody
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
MT-501
Phase 2
Undisclosed / early pipelineSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.